Clinical Trial

Adjuvant Sintilimab Plus Lenvatinib for HCC Characterized With VETC Following Liver Resection

Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
Vessels that encapsulate tumor clusters (VETC) are a novel invasive metastatic factor in hepatocellular carcinoma (HCC), operating independently of the epithelial-mesenchyme transition (EMT). The presence of VETC is associated with a higher rate of postoperative recurrence in HCC patients, indicating a more aggressive biological behavior.Improving the prognosis for VETC-positive patients is a critical issue in clinical oncology.
Trial Details
NCT Number NCT07077798
Lead Sponsor Wan-Guang Zhang
Conditions Hepatocellular Carcinoma (HCC)
Enrollment 234 participants
Start Date 2025-08-01
Primary Completion 2026-08-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-07-22